title: [Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer].
abstract: Since pharmacokinetics in patients undergoing hemodialysis differs from that in patients with normal renal function, chemotherapy for a hemodialysis patient should be considered with due care. We administered chemotherapy of modified FOLFOX6 to a patient on hemodialysis with inoperable metastatic colorectal cancer, and measured his plasma concentration of total platinum and non-protein-bound platinum. Since there is no reported case of oxaliplatin use in patients on hemodialysis so far, we evaluated whether it could be safely used for such patients. We made a dose escalation study with 40, 50, 60, 70 and 85 mg of oxaliplatin, and evaluated the pharmacokinetics at each dose. AUC was 5.67-10.21 mg/L x h. The dialysis removal rate was 84.0%. Although this patient could accept it relatively safely without any severe side effect, the optimal dosage and the timing of hemodialysis for inoperable metastatic colorectal cancer patients should be determined by a further study using more cases.
authors.affiliation: Department of Gastroenterological Surgery, Toranomon Hospital.
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Matoba
authors.forename: Toshihito
authors.initials: T
authors.lastname: Sawada
authors.forename: Shigeo
authors.initials: S
authors.lastname: Toda
authors.forename: Jin
authors.initials: J
authors.lastname: Moriyama
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Ehara
authors.forename: Shinji
authors.initials: S
authors.lastname: Mine
authors.forename: Masaki
authors.initials: M
authors.lastname: Ueno
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Masamichi
authors.initials: M
authors.lastname: Matsuda
authors.forename: Kenji
authors.initials: K
authors.lastname: Tsutsumi
authors.forename: Masaji
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Harushi
authors.initials: H
authors.lastname: Udagawa
authors.forename: Goro
authors.initials: G
authors.lastname: Watanabe
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Katori
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hayashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Igarashi
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Ito
authors.forename: Shinobu
authors.initials: S
authors.lastname: Hasebe
authors.forename: Mayumi
authors.initials: M
authors.lastname: Sato
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D009401:Nephrosis / Q000150:complications / Q000628:therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D006435:Renal Dialysis
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil